Ethinyl Estradiol 3 [KLH]

Smoltification and early seawater phase are critical developmental periods with physiological and biochemical changes in Atlantic salmon that facilitates survival in saltwater. MicroRNAs (miRNAs) are known to have important roles in development, but whether any miRNAs are involved in regulation of gene expression during smoltification and the adaption to seawater is largely unknown. Here, small RNA sequencing of materials from head kidney before, during smoltification and post seawater transfer were used to study expression dynamics of miRNAs, while microarray analysis was applied to study mRNA expression dynamics. Comparing all timepoints, 71 miRNAs and 2709 mRNAs were identified as differentially expressed (DE). Hierarchical clustering analysis of the DE miRNAs showed three major clusters with characteristic expression changes. Eighty-one DE mRNAs revealed negatively correlated expression patterns to DE miRNAs in Cluster I and III. Furthermore, 42 of these mRNAs were predicted as DE miRNA targets. Gene enrichment analysis of negatively correlated target genes showed they were enriched in gene ontology groups hormone biosynthesis, stress management, immune response, and ion transport. The results strongly indicate that post-transcriptional regulation of gene expression by miRNAs is important in smoltification and sea water adaption, and this study identifies several putative miRNA-target pairs for further functional studies.

Since synthetic hormones were first combined in the 1940s, hormone replacement therapy has been widely used by women experiencing undesirable menopausal symptoms. Subsequent research led to discoveries of several negative effects associated with the use of hormone therapy, sparking discussions on the risks versus benefits of hormonal treatment. Because of the risks associated with commercial preparations, compounded hormone therapy (CHT) has become more prominent, as it has been touted as a biologically equivalent alternative to synthetic hormones. However, because of minimal to no FDA oversight in the compounding realm generally, CHT may not be as safe as has been advertised. In 2018, based on favorable trial results, Bijuva became the first FDA-approved bioidentical combination 17-beta estradiol-progesterone formulation.